Chand Khanna (Ethos Veterinary Health)
Dr. Chand Khanna is a graduate of the Western College of Veterinary Medicine. He then received specialty training in the fields of veterinary internal medicine and oncology first at the Ontario Veterinary College, University of Guelph and then the University of Minnesota. Dr. Khanna is a Diplomate of the American College of Veterinary Internal Medicine (Oncology). Following this clinical specialization Dr. Khanna received a PhD in Pathobiology from the University of Minnesota and then completed a post-doctoral fellowship with Dr. Lee Helman in the Pediatric Oncology Branch of the National Cancer Institute in Bethesda Maryland. He was recently conferred honorary Diplomate status with the American College Veterinary Pathology.
Dr. Khanna continued his work at the National Cancer Institute as the Head of Pediatric Oncology Branch’s Tumor and Metastasis Biology Section, and the Founding Director of the Center for Cancer Research, Comparative Oncology Program. In 2011, Dr. Khanna was granted full tenure and promoted to the position of Senior Investigator at the National Cancer Institute. His research interests and responsibilities focused on the problem of cancer metastasis and the discovery of new options to treat patients with metastasis.. Dr. Khanna has over 100 publications in the area of cancer biology and therapy.
Dr. Khanna has maintained a strong connection to the field of veterinary oncology and animal health. He practiced as a veterinary oncologist within the referral oncology practices he founded and owned, The Oncology Service, based in the greater Washington, D.C. area. He is also the founder of Animal Clinical Investigation a contract research company, involved in complex medical problems seen in pets.
Dr. is currently the Chief Science Officer of Ethos Veterinary Health and President of the non-profit incubator of scientific innovation, Ethos Discovery (501c.3.). In these roles Dr. Khanna seeks to improve outcomes for human and pet patients with complex medical problems through the development of novel therapeutics and diagnostics.